<DOC>
	<DOCNO>NCT01660854</DOCNO>
	<brief_summary>In previous study ( NL33904.091.10 ) investigator challenge 24 volunteer Chloroquine Prophylaxis Sporozoites ( CPS ) immunization 45 , 30 15 infected mosquito-bites respectively . The availability immunize cohort open unique opportunity determine protection heterologous challenge protect unprotected volunteer previous challenge infection might serve immunological boost unprotected volunteer . In current observational , proof principle study , investigator aim investigate protection individual basis previously immunize challenged volunteer heterologous P. falciparum challenge .</brief_summary>
	<brief_title>Re-exposure Human Volunteers Heterologous Strain P. Falciparum Sporozoites</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Atovaquone , proguanil drug combination</mesh_term>
	<criteria>1 . Age ≥ 18 ≤ 35 year healthy volunteer ( male female ) 2 . Good health base history clinical examination 3 . Negative pregnancy test 4 . Use adequate contraception females 5 . Signing informed consent form , thereby demonstrate understand meaning procedure study 6 . Agreement inform general practitioner sign request release medical information concern contraindication participation study 7 . Willingness undergo Pf control challenge mosquito bite 8 . Agreement stay hotel room close trial centre part study ( Day 5 challenge till treatment finish ) 9 . Reachable ( 24/7 ) mobile phone whole study period 10 . Available attend study visit 11 . Agreement refrain blood donation Sanquin purpose , whole study period 12 . Willingness undergo HIV , hepatitis B hepatitis C test 13 . Negative urine toxicology screen test screen visit day challenge 14 . Willingness take curative regimen Malarone® 1 . History malaria ( participation ZonMw1 study ) residence malaria endemic area within past six month 2 . Plans travel malaria endemic area study period 3 . Plans travel outside Netherlands challenge period 4 . Previous participation malaria vaccine study and/or positive serology Pf ( except ZonMw1 volunteer ) 5 . Symptoms , physical sign laboratory value suggestive systemic disorder include renal , hepatic , cardiovascular , pulmonary , skin , immunodeficiency , psychiatric , condition could interfere interpretation study result compromise health volunteer 6 . History diabetes mellitus cancer ( except basal cell carcinoma skin ) 7 . History arrhythmia prolong QTinterval 8 . Positive family history 1st 2nd degree relative cardiac event &lt; 50 year old 9 . An estimate , ten year risk fatal cardiovascular disease ≥5 % , estimate Systematic Coronary Risk Evaluation ( SCORE ) system 10 . Clinically significant abnormality electrocardiogram ( ECG ) screen 11 . Body Mass Index ( BMI ) 18 30 kg/m2 12 . Any clinically significant deviation normal range biochemistry hematology blood test urine analysis 13 . Positive HIV , HBV HCV test 14 . Participation clinical study within 30 day prior onset study 15 . Enrollment clinical study study period 16 . For woman : pregnant lactate 17 . Volunteers unable give write informed consent 18 . Volunteers unable closely follow social , geographic psychological reason 19 . History drug alcohol abuse interfere normal social function 20 . A history treatment psychiatric disease 21 . A history convulsion 22 . Contraindications Malarone® , include hypersensitivity treatment take volunteer interfere Malarone® 23 . The use chronic immunosuppressive drug , antibiotic , immune modifying drug within three month study onset ( inhaled topical corticosteroid oral antihistaminic allow ) study period 24 . Any confirmed suspected immunosuppressive immunodeficient condition , include ( functional ) asplenia 25 . Coworkers trainees department Infectious Diseases , Medical Microbiology Parasitology Leiden University Medical Centre ( LUMC ) Medical Microbiology , Parasitology , Radboud University Nijmegen ( RUNMC ) 26 . A history sickle cell anaemia , sickle cell trait , thalassaemia ( trait ) , G6PD deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Plasmodium</keyword>
	<keyword>falciparum</keyword>
	<keyword>malaria</keyword>
	<keyword>heterologous</keyword>
	<keyword>immunity</keyword>
</DOC>